<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03983720</url>
  </required_header>
  <id_info>
    <org_study_id>19CH030</org_study_id>
    <secondary_id>2019-A00427-50</secondary_id>
    <nct_id>NCT03983720</nct_id>
  </id_info>
  <brief_title>Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?</brief_title>
  <acronym>FatSEP</acronym>
  <official_title>Can Fatigability Neuromuscular Explain Chronic Fatigue in People With Multiple Sclerosis?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic fatigue is the most common and debilitating symptom in multiple sclerosis patients.&#xD;
      This chronic fatigue affects their quality of life by decreasing their capacity to perform&#xD;
      simple tasks of daily life.&#xD;
&#xD;
      The aim of the present project is to determine whether deteriorated neuromuscular function&#xD;
      (i.e. increased fatigability) is involved in this feeling of chronic fatigue. Because the&#xD;
      causes of this feeling are multi-dimensional, a large battery of tests will allow us to&#xD;
      better understand the origin of chronic fatigue. A better knowledge of chronic fatigue&#xD;
      etiology will allow to optimize rehabilitation treatments to decrease the&#xD;
      apparition/persistence of chronic fatigue and in fine improve quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Voluntary maximum contraction</measure>
    <time_frame>Day : 30</time_frame>
    <description>Comparison the percentage of decrease in voluntary maximum contraction reported after the fatiguing task. Measured by an instrumented measuring pedal (PowerForce pedal, Model PF1.0.0.0, Radlabor GmbH, Freiburg, Germany)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuromuscular function during the dynamic strenuous exercise</measure>
    <time_frame>Day : 30</time_frame>
    <description>Cortical activity by transcranial magnetic stimulation, evaluated by recording of the evoked motor potentials&#xD;
.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle oxygen extraction capacity</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by near-infrared spectroscopy (NIRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anemia</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by blood count in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by C-reactiv protein in blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by effort test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by heart rate monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive fatigue</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by Symbol Digit Modalities Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perceived fatigue</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by Borg scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thermoregulation</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by digestible thermometric pill (e-celcius Performance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by actigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle volume</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by Magnetic Resonance Imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic fatigue</measure>
    <time_frame>Day : 30</time_frame>
    <description>Measured by a Phosphorus 31 Nuclear Magnetic Resonance test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sclerosis, Multiple</condition>
  <arm_group>
    <arm_group_label>Patient with multiple sclerosis and lowly fatigued</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with multiple sclerosis and lowly fatigued will be included.&#xD;
They will have:&#xD;
Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient with multiple sclerosis and highly fatigued</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with multiple sclerosis and highly fatigued will be included. They will have:&#xD;
Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy subjects will be included. They will have:&#xD;
Visit 1 (day 0) = Questionnaires, blood sample, cardiopulmonary evaluation, capacity of muscular oxygen extraction, sleep assessment Visit 2 (day 15) = Neuromuscular evaluation Visit 3 (day 30) = Metabolic fatigue</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluation of degree chronic fatigue.</intervention_name>
    <description>Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.</description>
    <arm_group_label>Patient with multiple sclerosis and highly fatigued</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and lowly fatigued</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Fatigue Severity Scale (FSS)&#xD;
Modified Fatigue Impact Scale (MFIS)&#xD;
Godin Leisure-Time Exercise Questionnaire (GLTEQ)&#xD;
Scale of life quality of multiple sclerosis (SEP-59)&#xD;
Center for Epidemiologic Studies Depression (CES-D)&#xD;
Pittsburgh Sleep Quality Index (PSQ-I)</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and highly fatigued</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and lowly fatigued</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood sample will be realized to evaluate anemia and inflammations.</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and highly fatigued</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and lowly fatigued</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cardiopulmonary evaluation</intervention_name>
    <description>Cardiopulmonary evaluation will be realized with a cycle ergometer.</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and highly fatigued</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and lowly fatigued</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Capacity of muscular oxygen extraction</intervention_name>
    <description>Measure the capacity of muscular oxygen extraction with a cycle ergometer.</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and highly fatigued</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and lowly fatigued</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sleep assessment</intervention_name>
    <description>Sleep assessment will be measured by actigraphy during 15 days.</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and highly fatigued</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and lowly fatigued</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Metabolic fatigue</intervention_name>
    <description>Metabolic fatigue will be measured by Magnetic Resonance Imaging (MRI).</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and highly fatigued</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and lowly fatigued</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuromuscular evaluation</intervention_name>
    <description>Neuromuscular evaluation will be measured by the composite of the results of:&#xD;
Fatigue test&#xD;
Measure of voluntary isometric force&#xD;
Surface electromyography&#xD;
Peripheral nerve stimulation&#xD;
Transcranial Magnetic Stimulation (TMS)&#xD;
Perceived fatigue&#xD;
Cognitive fatigue&#xD;
Thermoregulation</description>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and highly fatigued</arm_group_label>
    <arm_group_label>Patient with multiple sclerosis and lowly fatigued</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For Patients:&#xD;
&#xD;
          -  Aged ≥ 18 and ≤ 70 years&#xD;
&#xD;
          -  Men or women&#xD;
&#xD;
          -  With multiple sclerosis since 2 and 25 years&#xD;
&#xD;
          -  Affiliates or beneficiaries of social security scheme&#xD;
&#xD;
          -  Signed consent&#xD;
&#xD;
        For Healthy volunteers:&#xD;
&#xD;
          -  Aged ≥ 18 and ≤ 70 years&#xD;
&#xD;
          -  Men or women&#xD;
&#xD;
          -  Matched in accordance with age, sex and level of physical activity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For Patients and Healthy volunteers:&#xD;
&#xD;
          -  High heart rate resting&#xD;
&#xD;
          -  Blood pressure &gt; 144/94 mmHg&#xD;
&#xD;
          -  Recent adjustment of drug or drug can have an impact on fatigue or stimulant for&#xD;
             fatigue&#xD;
&#xD;
          -  Taking neuroactive substances that can alter corticospinal excitability&#xD;
&#xD;
          -  Contraindication at application magnetic field&#xD;
&#xD;
          -  Contraindication at Magnetic Resonance Imaging (MRI)&#xD;
&#xD;
          -  Currently participating in a structured exercise program&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
        For Patients only:&#xD;
&#xD;
          -  Spasticity or cerebellar ataxia&#xD;
&#xD;
          -  Abnormal range of motion (toe and/or ankle)&#xD;
&#xD;
          -  Musculoskeletal injuries that impedes pedaling&#xD;
&#xD;
          -  Appearance of symptoms of multiple sclerosis in the 90 days preceding the study&#xD;
&#xD;
        For Healthy volunteers:&#xD;
&#xD;
        - Neurological diseases, cardiovascular, musculoskeletal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe CAMDESSANCHE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU DE SAINT ETIENNE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-Philippe CAMDESSANCHE, MD PhD</last_name>
    <phone>(0)477120559</phone>
    <phone_ext>+33</phone_ext>
    <email>j.philippe.camdessanche@chu-st-etienne.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amandine BAUDOT, CRA</last_name>
    <phone>(0)477829450</phone>
    <phone_ext>+33</phone_ext>
    <email>amandine.baudot@chu-st-etienne.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Saint-Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Philippe CAMDESSANCHE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence ROBERT-VARVAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud LACOUR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure MAZZOLA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélanie FORESTIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre CROISILLE, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Léonard FEASSON, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep assessment</keyword>
  <keyword>Neuromuscular Fatigability</keyword>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Chronic fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

